Who Supplies Plasma to India from IRELAND

To import finished pharmaceutical formulations containing plasma into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 41 for registration and Form 10 for the import license. The registration certificate is valid for three years and requires a fee of $1,500 USD. The import license is also valid for three years. The application process typically takes up to nine months.

Imported pharmaceutical formulations containing plasma must undergo quality testing at CDSCO-approved laboratories. Three consecutive batches are required for testing, with samples provided for reanalysis. The manufacturer must submit a Certificate of Analysis (CoA) from the exporting country's laboratory, along with stability data compliant with ICH Zone IV standards. The product must meet the standards of the Indian Pharmacopoeia. Port inspection by customs drug inspectors is mandatory to ensure compliance with these requirements.

In April 2025, the CDSCO mandated that all imported drugs, including finished formulations containing plasma, must have an Import Registration Certificate and Import License. This regulation aims to prevent the sale of unapproved or illegal medicines in the Indian market.

India imports finished pharmaceutical formulations containing plasma to access patented or branded products, specialized dosage forms, and formulations not manufactured domestically. The domestic capacity may not meet the demand for certain plasma-based formulations, leading to reliance on imports. The market size for such imports is significant, with a total value of $2.8 million across 215 exporters to 90 countries.

The import duty for finished pharmaceutical formulations containing plasma under HS Code 30029010 includes a 10% Basic Customs Duty, 2% Education Cess, and 1% Secondary Higher Education Cess, totaling 10.30%. Additionally, the Integrated Goods and Services Tax (IGST) is applicable at 0%. Anti-dumping duties and exemption notifications may apply based on specific circumstances.

India sources finished pharmaceutical formulations containing plasma from Ireland due to the country's competitive advantages, including patents, specialized dosage forms, and high-quality manufacturing standards. Other suppliers, such as China, Germany, and the United States, also contribute to the market, but Ireland's share remains notable.

India imports finished pharmaceutical formulations containing plasma from Ireland to access patented formulations, specialized dosage forms, and high-quality products not available domestically. Ireland's advanced manufacturing capabilities and adherence to international quality standards make it a preferred source.

Compared to other origins like China, Germany, and the United States, Ireland offers competitive pricing, superior quality, and reliable regulatory compliance. Ireland's unique advantage lies in its specialized formulations and adherence to stringent quality standards.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. There have been no significant shortages reported in recent years.

1. 1Engage in dual-sourcing strategies to mitigate supply chain risks.
2. 2Implement robust inventory planning to manage lead times effectively.
3. 3Establish favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Negotiate Minimum Order Quantities (MOQs) that align with demand forecasts.
5. 5Conduct thorough supplier qualification processes to ensure compliance with quality and regulatory standards.

1. 1Obtain a valid Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT).
2. 2Register the manufacturing premises with CDSCO using Form 41.
3. 3Register each drug product with CDSCO using Form 10.
4. 4Obtain a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare, if required.
5. 5Engage a licensed customs broker for customs clearance.
6. 6Seek an advance ruling for HS Code 30029010, if necessary.

1. 1Certificate of Analysis (CoA) from the exporting country's laboratory.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practice (GMP) certificate.
4. 4Drug Master File (DMF).
5. 5Stability data compliant with ICH Zone IV standards.
6. 6Free Sale Certificate.
7. 7Manufacturer's authorization letter.

Upon arrival, customs drug inspectors collect samples for mandatory batch testing. The testing process includes verifying the Certificate of Analysis (CoA) and stability data. If a batch fails to meet the required standards, it may be rejected, leading to potential delays or additional costs. Common quality issues from Ireland have not been reported.

The Import Registration Certificate and Import License require renewal every three years. Periodic audits in Ireland may be conducted to ensure compliance with manufacturing standards. Any changes in the manufacturing process, packaging, labeling, testing, or documentation must be reported. Post-import monitoring and pharmacovigilance are essential to ensure ongoing product safety and efficacy. Import records must be maintained as per the Drug and Cosmetics Act.